MGRX

MangoCeuticals is a men's-health telemedicine micro-cap that is going backwards on every operating axis. FY2025 revenue was just $456K and FELL 26% YoY — the third straight annual decline from the $731K FY2023 peak — while the net loss ballooned to -$20.6M (from -$8.7M). Even the 54.9% gross margin is meaningless at this scale: operating margin is -3,954% and net margin -4,527%. This isn't an early-stage growth story; it's a business whose top line is eroding while losses accelerate.

The balance sheet looks superficially clean (liabilities/equity just 0.06x, $15.2M equity) but that solvency is an illusion sitting on a lit fuse. Operating cash flow was -$5.85M against only $1.49M of cash, so the company cannot fund even one more year of its current burn. Management says so directly: it 'anticipate[s] the need for additional funding in order to continue our operations at their current levels' over the next 12 months, and warns any raise 'may result in significant dilution to existing shareholders.' Shares already grew 228% in a single year, and the -$40.6M accumulated deficit shows how this movie ends — new stock funds the losses and existing holders get crushed.